SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 55 of 94
Word Count: 1426
Character Count: 9607

Document Content:

the chairman of the Audit Committee. Each of our Audit Committee members will satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. Our board of directors has determined that Mark Ravich possesses accounting or related financial management experience that qualifies her as an “audit committee financial expert” as defined by the rules and regulations of the SEC. Our Audit Committee oversees our accounting and financial reporting processes and the audits of our financial statements. Our Audit Committee will perform several functions, including: ● evaluating the performance, independence and qualifications of our independent registered public accounting firm and determining whether to retain our existing independent registered public accounting firm or engage new independent registered public accounting firm; ● reviewing and approving the engagement of our independent registered public accounting firm to perform audit services and any permissible non-audit services;

●	reviewing
our annual and quarterly financial statements and reports, including the disclosures contained under the caption “ Management’s
Discussion and Analysis of Financial Condition and Results of Operations ,” and discussing the statements and reports with
our independent registered public accounting firm and management;

●	reviewing
with our independent registered public accounting firm and management significant issues that arise regarding accounting principles
and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;

●	reviewing
our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk
management is implemented; and

●	reviewing
and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.

Compensation
Committee

Ravich, Dr. Abraham and Dr. Puri will serve as members of our Compensation Committee with Mr. Ravich serving as the chairman of the
Compensation Committee. All of our Compensation
Committee members satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards
under Rule 10A-3 under the Exchange Act. The functions of this committee include, among other things:

●	reviewing,
modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall
compensation strategy and policies;

●	reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment
of our executive officers;

●	reviewing
and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive
plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and
programs;

●	reviewing
and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory
arrangements for our executive officers;

●	reviewing
with management and approving our disclosures under the caption “ Compensation Discussion and Analysis ” in our
periodic reports or proxy statements to be filed with the SEC; and

●	preparing
the report that the SEC requires in our annual proxy statement.

Nominating
and Corporate Governance Committee

Ravich, Dr. Abraham, and Dr. Puri will serve as members of our Nominating and Corporate Governance Committee with Dr. Abraham
serving as the chairman of the Nominating and Corporate Governance Committee. All of our Nominating and Corporate Governance Committee
members will satisfy the “independence” requirements of the Nasdaq listing rules and meet the independence standards under
Rule 10A-3 under the Exchange Act. The functions of this committee include, among other things:

●	identifying,
reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;

●	evaluating
director performance on the board and applicable committees of the board and determining whether continued service on our board is
appropriate;

●	evaluating,
nominating and recommending individuals for membership on our board of directors; and

●	evaluating
nominations by stockholders of candidates for election to our board of directors.

The
nominating and corporate governance committee will take into account many factors in determining recommendations for persons to serve
on the board of directors, including the following:

●	personal
and professional integrity, ethics and values;

●	experience
in corporate management, such as serving as an officer or former officer of a publicly-held company;

●	experience
as a board member or executive officer of another publicly-held company;

●	strong
finance experience;

●	diversity
of expertise and experience in substantive matters pertaining to our business relative to other board members;

●	diversity
of background and perspective including, without limitation, with respect to age, gender, race, place of residence and specialized
experience;

●	experience
relevant to our business industry and with relevant social policy concerns; and

●	relevant
academic expertise or other proficiency in an area of our business operations.

Role
of Board in Risk Oversight Process

Periodically,
our board of directors assesses these roles and the board of directors leadership structure to ensure the interests of our company and
our stockholders are best served. Our board of directors has determined that its current leadership structure is appropriate.

While
management is responsible for assessing and managing risks to our company, our board of directors is responsible for overseeing management’s
efforts to assess and manage risk. This oversight is conducted primarily by our full board of directors, which has responsibility for
general oversight of risks, and standing committees of our board of directors. Our board of directors satisfies this responsibility through
full reports by each committee chair regarding the committee’s considerations and actions, as well as through regular reports directly
from officers responsible for oversight of particular risks within our company. Our board of directors believes that full and open communications
between management and the board of directors are essential for effective risk management and oversight.

Compensation
Committee Interlocks and Insider Participation

None
of our executive officers serves, or in the past has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of our board of
directors or our compensation committee. None of the members of our compensation committee is, or has ever been, an officer or employee
of our company.

Clawback
Policy

will adopt a compensation recovery policy that is compliant with Nasdaq listing rules as required by the Dodd-Frank Act.

Code
of Business Conduct and Ethics

or prior to the completion of this offering, we will adopt a written code of business conduct and ethics that applies to our employees,
officers and directors. A current copy of the code will be posted on the Corporate Governance section of our website, which will be located
at www.bioventrix.com. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics,
or waivers of such provisions applicable to any principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions, and our directors, on our website identified above or in filings with the SEC.

Involvement
in Certain Legal Proceedings

Except
as otherwise disclosed below, to the best of our knowledge, none of our directors or executive officers has, during
the past ten years:

●	been
convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses);

●	had
any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business
association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years
prior to that time. Mr. Ravich served as a director of Orchids Paper Products Company from February 2013 to 2018, as well as chairman
of the governance committee and as a member of the audit committee. Orchids Paper Products Company filed for Chapter 11 bankruptcy
on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware;

●	been
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, by any court of competent jurisdiction
or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in
any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be
associated with persons engaged in any such activity;

●	been
found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;